This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Press release | Umeå January 14, 2022

Lipigon has successfully completed another preclinical study with drug candidate Lipisense

Lipigon Pharmaceuticals AB (”Lipigon”), which is developing therapeutics for lipid-related diseases, today announced it has completed another safety study with the drug candidate Lipisense yielding positive results.

The reported study aimed to investigate cardiovascular safety and focused on identifying any specific effects on the heart and blood vessels. The results show that Lipisense was well tolerated in high doses and did not cause any serious effect on the studied parameters. Together with the other preclinical safety studies, these data will form the basis for a clinical trial application that is expected to be submitted in the first quarter of 2022.

Lipisense is a drug candidate for the treatment of diseases with abnormal levels of lipids in the blood, primarily triglycerides, and a first-in-class treatment with a unique mechanism of action. Elevated triglycerides are a risk factor present in several diseases and Lipisense has the potential to normalize triglyceride levels. The large population of patients with elevated triglycerides is heterogeneous—comprising patients with rare genetic disorders to large patient groups, such as type 2 diabetics.

CEO Stefan K. Nilsson comments:
“With this safety study that shows no serious cardiovascular effects and previous positive safety and efficacy data, the Lipisense project is progressing according to plan. Now only the results from one additional preclinical safety study remain, which we will report on shortly before we can apply for the start of clinical studies. We are on schedule and look forward to starting the first-in-human study during the second quarter this year.”

About Lipisense
The drug candidate is an RNA therapeutics that prevents the cells from producing the disease-promoting target protein ANGPTL4 by destroying the protein-coding RNA before the target protein has been formed. The target gene has a strong genetic association to plasma lipid levels and related diseases, such as type 2 diabetes and cardiovascular disease.



Tvistevägen 48 C, SE-90736 Umeå, Sweden
Tel: +46(0)705781768, info@lipigon.se
Org.nr: 556810-9077
lipigon.se

For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: stefan@lipigon.se
Phone: +46 705 78 17 68

This is information that Lipigon Pharmaceuticals AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:45 am CET, on 14 January 2022.

About Lipigon
Lipigon develops novel therapeutics for patients with lipid metabolism disorders. The company is based on over 50 years of lipid research at Umeå University, Sweden. Lipigon's initial focus is on orphan drugs and niche indications, but in the long term, the company will have the opportunity to target broader indications in the area, such as diabetes and cardiovascular disease. Lipigon's pipeline includes four active projects: the RNA-drug Lipisense for treatment of hypertriglyceridemia; an RNA-drug for treatment of acute respiratory distress syndrome; a gene therapy treatment for the rare disease lipodystrophy, together with Combigene AB (publ); and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc).

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.